



By Carolyn Gretton

▶ PHARMACEUTICAL POOL

Dr. Anirvan GHOSH

ROCHE SELECTS HEAD OF CNS DISCOVERY



Global healthcare company Roche has named Anirvan Ghosh, Ph.D., head of discovery for central nervous system (CNS). Dr. Ghosh is based at Roche's pharma research and early development organization in Basel, Switzerland, and oversees discovery research in the CNS discovery and translational area. He joins Roche from the University of California, San Diego. He received a Ph.D. in neuroscience from Stanford University.

Wolf KUPATT

Paul MARTIN

BAXTER ELECTS CORPORATE OFFICERS



Global healthcare company Baxter International has appointed Wolf Kupatt, president of Latin America and Canada, to serve as a corporate officer. Mr. Kupatt was promoted to his current position in 2010, after serving as general manager for Baxter's operations in Germany.

Paul Martin, who joined Baxter earlier this year as chief information officer, has also been appointed to serve as an officer of the company. Mr. Martin was previously group chief information officer for Rexam.

Mark MATTHEWS

POZEN APPOINTS MARKETING VP



Mark Matthews has joined Pozen as VP of marketing and sales, responsible for driving commercial strategy for all pipeline products beginning with the pharma company's lead product candidate, PA32540, a coordinated-delivery tablet of enteric-coated aspirin and immediate-release omeprazole. Before joining Pozen, Mr. Matthews held several key commercial positions, including VP of marketing and sales at Javelin Pharmaceuticals and VP of neurology marketing at Biogen Idec.

Dr. Greg PLOWMAN

LILLY TAPS FORMER GENENTECH DIRECTOR TO HEAD ONCOLOGY RESEARCH



Greg Plowman, M.D., Ph.D., has joined global pharmaceutical company Lilly as VP, oncology research, and senior VP of ImClone Systems research. Dr. Plowman is responsible for overseeing the

oncology research efforts of both Lilly and its ImClone subsidiary from ImClone's research center at the Alexandria Center for Life Science – New York City. Dr. Plowman joins Lilly following six years as a senior director of research for Genentech, a member of the Roche Group. He earned an M.D. and a Ph.D. from the University of Washington.

BIOTECHNOLOGY POOL

▶ Kevin HEYECK

ALLOCURE NAMES BUSINESS CHIEF



AlloCure, a biotechnology company developing innovative therapies for the treatment of kidney disease, has appointed Kevin Heyeck chief business officer. Mr. Heyeck was previously VP, business development for Vitae Pharmaceuticals.

BIOPHARMACEUTICAL POOL

▶ Dr. Diane TRIBBLE

AEGERION NAMES SCIENTIFIC CHIEF



Aegerion Pharmaceuticals, a biopharma company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, has appointed Diane Tribble, Ph.D., chief scientific officer. Dr. Tribble was most recently VP of clinical development at Isis Pharmaceuticals.

DEVICE POOL

▶ Jose (Joe) ALMEIDA

COVIDIEN ANNOUNCES CEO SUCCESSION



Global healthcare products company Covidien has announced the selection of Jose (Joe) Almeida to succeed Richard Meelia as president and CEO upon Mr. Meelia's retirement July 1. Mr. Meelia will serve as non-executive chairman of Covidien's board for a transition period of up to one year following his retirement.

Mr. Almeida, who joined the former Tyco Healthcare in 1995, currently serves as president of Covidien's medical devices business.

▶ ASSOCIATION POOL

Marc BEER

BIO NAMES AEGERION CEO TO EMERGING COMPANIES BOARD

The Biotechnology Industry Organization (BIO)



board.

has appointed Aegerion Pharmaceuticals CEO Marc Beer to its board of directors as a member of the emerging companies section governing

board. Mr. Beer brings to the emerging companies board his experience in guiding companies from the development stage through commercialization, and he is collaborating to serve the needs of small- to medium-sized BIO member companies.

▶ AGENCY POOL

April ANDRADE

Mary Jane CHEAH

Bernard FALKOFF

Jill KU

Kelly MCPARTLAND

Daniel TRIPO

Jennifer VERLANGIERI

HEALTHED BOLSTERS ACCOUNT, CREATIVE TEAMS



HealthEd, a specialized agency focused on turning education into positive health outcomes, has announced a number of new hires.



April Andrade joins HealthEd as account supervisor, from the same role at ICC.



Mary Jane Cheah has been appointed assistant director, editorial services. Ms. Cheah previously held the same position at Forest Laboratories. She received an M.A. in industrial psychology from Fairleigh Dickinson University.



Bernard Falkoff has been named senior copywriter. Mr. Falkoff was previously director, strategic engagement, for customediabios.



Jill Ku has joined HealthEd as senior art director. Ms. Ku has design experience with several agencies, including Edelman, CementBond, CDMI Connect, Wunderman, and Torre Lazur McCann. She received an M.A. in art education from New York University.



Kelly McPartland has been appointed senior account executive. Ms. McPartland was most recently senior account executive for Euro RSCG Life

Catapult.

Daniel Tripo has been named director, information technology. Mr. Tripo's previous experience includes serving as the network infrastructure man-



ager for Frazier Industrial Company, as well as network administrator roles with CSAV and ICP.

Jennifer Verlangieri has been hired as an editor. Ms. Verlangieri previously served as an editor at Biolumina and Quadrant HealthCom.

Dr. Larry **BLANDFORD**

Carlos **DELUCCA**

Jorge **FONT**

Steven **GOLDSTEIN**

Dana **REGAN**

HOBERT EXPANDS EXECUTIVE TEAM



Full-service managed markets healthcare agency The Hobart Group has added several industry experts and seasoned managed market executives to its staff.



Larry Blandford, Pharm.D., has joined Hobart as senior VP, strategic services. Dr. Blandford was previously area VP for CVS Caremark.



Carlos Delucca has been named executive VP, strategic services. Mr. Delucca has more than 16 years of healthcare experience, with 14 years on the client side within multiple leadership capacities, including managed markets, marketing, sales, and operations at UCB.



Jorge Font has been appointed senior VP, benefits industry innovation. Mr. Font is a former principal at Buck Consultants with more than 25 years of experience in the employee benefits and healthcare industries.



Steven Goldstein brings more than 22 years in healthcare communications to Hobart as senior VP, creative director.

Dana Regan has been named executive VP, director of client services. Ms. Regan has experience in managed market strategy and execution, having previously served in senior leadership roles on the agency and industry sides, including stints at Ogilvy Payer Marketing, Torre Lazur Managed Markets, BD, Wyeth, and Purdue Pharma.

Joanna **BLIGH**

Olivia **GANGUZZA**

James **REILLY**

David **TEMPLETON**

NEW STAFF AT NATREL

Natrel Communications has added staff to its rapidly expanding creative and account services departments.

Joanna Bligh has joined Natrel as senior editor.



Ms. Bligh was previously a medical editor at OptumHealth Education.



Olivia Ganguzza has been named senior account executive. Ms. Ganguzza was previously a diabetes care specialist at Novo Nordisk.



James Reilly has been appointed VP, account group supervisor. Mr. Reilly has more than 20 years of marketing experience in the pharmaceutical and biologics industries and has held marketing leadership positions and business intelligence posts at Rhone-Poulenc Rorer (now Sanofi-Aventis), CSL Behring, and King Pharmaceuticals.



David Templeton has been named VP, account group supervisor. Mr. Templeton has more than two decades experience as a strategic leader in the pharmaceutical industry, with a combination of commercial, analytic, and scientific expertise.

Kate **CHRISTIANSEN**

Kristin **GLUNZ**

Meredith **KEROFF**

ABELSONTAYLOR PROMOTES ACCOUNT DIRECTORS



Independent healthcare advertising agency AbelsonTaylor has promoted Kate Christiansen, Kristin Glunz, and Meredith Keroff to account director from senior account supervisor.



Ms. Christiansen continues to manage the agency's consumer infant nutrition account, focusing on strategy in healthcare professional (HCP) channels and alignment of the agency HCP and consumer initiatives for the brand.



Ms. Glunz provides strategic and tactical counsel for a consumer infant nutrition product, focusing on consumer brand strategy and alignment of the agency's consumer and professional initiatives for the brand.

Ms. Keroff continues to spearhead anti-infective accounts for AbelsonTaylor, as well as the launch of a pain management drug.

Ms. Keroff continues to spearhead anti-infective accounts for AbelsonTaylor, as well as the launch of a pain management drug.

Jennifer **COMITEAU**

VETERAN ADWEEK EDITOR JOINS DRAFTFCB



Draftfcb has named Jennifer Comiteau director of content creation, charged with bolstering the global marketing agency's position in the marketplace and sharing insights and information

about innovative practices developed for clients and the executives behind their development. Ms. Comiteau oversees the agency's New York communications department. She joins Draftfcb after more than 15 years at Adweek, where she served as a reporter, editor, and, most recently, director of content/custom media.

Amber **EATON**

Abby **MORRIS**

MICROMASS BOLSTERS ACCOUNT GROUP



MicroMass Communications, an agency focused on behavioral marketing in the healthcare industry, has added to its account management team.



Amber Eaton has joined MicroMass as account supervisor, handling products for the treatment of immune deficiencies and cold sores. Ms. Eaton was most recently client service manager for p-value communications.

Abby Morris has been appointed account executive, working on a product for the treatment of hypertension. Ms. Morris was previously account executive at GSW Worldwide.

Matt **FOREMAN**

PHOTOSOUND PROMOTES ACCOUNT DIRECTOR



Global brand communications agency Photosound, a HealthSTAR company, has promoted Matt Foreman to the senior role of account director with the global client strategy group.

Kierston **GEDEON**

Patti **HABIG**

Shannon **HARTLEY**

Frank **IQBAL**

ROSETTA PROMOTES FOUR PARTNERS



Independent digital and direct interactive agency Rosetta has announced four promotions among its team of partners.



Kierston Gedeon has been promoted to partner within Rosetta's people services group, based in Cleveland. Ms. Gedeon joined the agency in 2006.



Patti Habig has been elevated to partner in the healthcare group, based in Princeton, N.J. Ms. Habig has been with Rosetta since 2008.

Shannon Hartley, who joined Rosetta as a partner in 2006, has been promoted to managing partner and member of



Rosetta's executive leadership team. Ms. Hartley leads the project management department for Rosetta Healthcare while continuing her client-focused role as a healthcare and Rosetta consulting practice leader. She is based in the Princeton office.

Frank Iqbal has been appointed partner within Rosetta's creative and customer experience group, based in New York. Mr. Iqbal has been with Rosetta since 2008.

Patrick O'SHEA

Jeff SHEIN

STAFF GROWTH AT FINGERPAINT MARKETING



Integrated marketing and advertising agency FingerPaint Marketing has named Patrick O'Shea a partner and head of account services. Mr. O'Shea was most recently senior VP of account management for inVentiv Health.



In other moves, Jeff Shein has joined FingerPaint as head of IT solutions. Mr. Shein was previously IT manager for Momentum Worldwide.

Suzanne SEGAL

HARRISON AND STAR APPOINTS CUSTOMER RELATIONSHIP VP



Harrison and Star, part of the Omnicom network of agencies, has named Suzanne Segal VP of customer relationship marketing. Ms. Segal leads the strategic development of the agency's CRM programs from planning through execution. She was previously VP/director marketing for Digitas Health.

Aaron STROUT

WCG ENHANCES SOCIAL MEDIA TEAM



WCG, a global independent company offering integrated creative, interactive, and marketing communications services to clients in healthcare, consumer products, and technology, has appointed Aaron Strout social media group director. In addition to building and leading location-based marketing as part of the firm's broader mobile marketing program offerings, Mr. Strout serves as strategic counsel to WCG's growing number of clients. He was previously chief marketing officer for Powder.

Dr. Daniel ZAKSAS

DUDNYK EXPANDS SCIENTIFIC DEPARTMENT

Daniel Zaksas, Ph.D., has joined Dudnyk as scientific director, responsible for overseeing the medical content of the independent healthcare



agency's promotional copy. Dr. Zaksas was previously a senior medical writer at Complete Healthcare Communications. He received his doctorate in neuroscience from the University of Rochester and completed a postdoctoral fellowship at Harvard Medical School.

CONSULTING POOL

Gary KEILTY

HURON CONSULTING NAMES COMPLIANCE & INVESTIGATION DIRECTOR



Huron Consulting Group has named Gary Keilty as a managing director in Huron Healthcare's compliance & investigations solution. Mr. Keilty specializes in providing forensic investigation, dispute resolution, regulatory compliance, and acquisition due diligence services. Before joining Huron Healthcare, Mr. Keilty worked in the national health sciences practices of Deloitte Financial Advisory Services and Navigant Consulting.

CRO POOL

Dr. Martha FELLER

KENDLE NAMES VP



Global full-service CRO Kendle has named Martha Feller, Ph.D., VP and global head, study start-up. Dr. Feller's responsibilities include leading study start-up management, site identification, site start-up, clinical trial regulatory, investigator contracts, and essential document collection.

Dr. Feller rejoins Kendle after two years with i3 Research, where she was executive VP, global operations. She earned a doctorate in biochemistry from the University of Cincinnati College of Medicine.

Dr. Jeffrey FREITAG

PHARMANET APPOINTS MEDICAL CHIEF



PharmaNet Development Group, a provider of clinical development services to pharmaceutical, biotechnology, generic drug, and medical device companies, has appointed Jeffrey Freitag, M.D., senior VP, PharmaNet Consulting, to the expanded role of chief medical officer. He continues to head a team of regulatory and pharmaceutical consultants.

Patrick MELVIN

Bruce WAKEMAN

INC RESEARCH STRENGTHENS ONCOLOGY, ALLIANCE DEVELOPMENT STAFF



Patrick Melvin has joined therapeutically focused CRO INC Research as executive director, oncology, leveraging his extensive hematology/oncology trial experience for Phase I first-in-human studies through pivotal global Phase IV programs. Mr. Melvin has experience in clinical drug development in hematology and oncology at such companies as PPD and Premier Research.



INC Research also has appointed Bruce Wakeman VP of alliance development, with responsibility for further expanding the CRO's clinical delivery alliance services to address customers' wide-ranging needs. Mr. Wakeman was most recently VP, U.S. business development, for Premier Research.

SERVICE POOL

June DAVIS

Chris SHEPARD

Robert WEBSTER

MEDMEME MAKES NEW ADDITIONS



MedMeme, a provider of key opinion leader and competitive intelligence data to the healthcare, pharmaceutical, and biotechnical industries, has added two sales executives and a content services manager to its team.



June Davis has been named VP of sales. Ms. Davis was most recently director of strategic accounts for WebMD.



As manager of content services, Chris Shepard oversees the identification, tracking, and compiling of data from the thousands of medical conferences covered by MedMeme. Mr. Shepard brings extensive experience in and a broad understanding of the field of medical meeting content, having held similar content services positions at Medical Intelligence Solutions and Rogers.

Robert Webster has joined MedMeme as executive VP of sales, responsible for overseeing all company sales and marketing activities. Mr. Webster was previously managing director for Prisma Pharmaceuticals in the United Kingdom.

James ELLIOTT

Chris GOINS

TGAS ADVISORS EXPANDS TRAINING & DEVELOPMENT TEAM



Benchmarking and advisory services firm TGaS Advisors, a division of KnowledgePoint360, has named two management advisors to lead its fast-growing training & development solution.

James Elliott serves as director, management advisor, for the training and development solution.



Mr. Elliott was most recently team lead, neuroscience training, at Bristol-Myers Squibb.

Chris Goins has been named VP, management advisor, for the solution. Mr. Goins was most recently executive director, sales training and management development, for Pfizer.

Dr. Camm EPSTEIN

Heinz OHDE

Dr. Marco RAULAND

GfK HEALTHCARE HIRES SENIOR RESEARCH PROFESSIONALS



GfK HealthCare, a global provider of fully integrated custom healthcare marketing research, has expanded its global research operations with three senior-level appointments.



Camm Epstein, Ph.D., has joined GfK HealthCare as VP, market access – U.S. practice lead. Dr. Epstein is responsible for describing current and predicting future market access, as well as measuring payer reactions to pricing and contracting, new products and market events, sales and marketing, and health economics and outcomes research.



Before joining GfK HealthCare, Dr. Epstein built and led a managed markets research practice for

MediMedia. He received an MPH from Columbia University and a Ph.D. in public administration from New York University.

Heinz Ohde has been named division manager, global syndicated services based in Nuremberg, Germany. Mr. Ohde is responsible for the international growth of GfK HealthCare's syndicated services. He most recently served as business development director at Cegedim Strategic Data in Paris.

Marco Rauland, Ph.D., has been appointed head of pricing and reimbursement, helping to shape clients' global pricing and reimbursement strategies and foster their local implementation.

Dr. Rauland is relying on GfK HealthCare's expertise from various countries to analyze the effects of changes within the local healthcare systems on innovative pricing and market access strategies.

Dr. Rauland previously served as global head of the pricing, access, and reimbursement practice for Genactis. He holds a Ph.D. in natural science from the University of Cologne in Germany.



dictive modeling to the health sciences industry, has appointed Joann Flynn marketing manager.

Ms. Flynn most recently ran her own nutrition consulting company, Designs for Wellness.

She earned an M.S. from the University of Bridgeport.

Elna Hamp has been named VP, business development. Ms. Hamp was previously VP of sales and marketing for Verisys.



Brian TVENSTRUP

MTI NAMES BUSINESS ANALYTICS VP



MTI Information Technologies has appointed Brian Tvenstrup senior VP, business analytics.

Mr. Tvenstrup is responsible for leading the MTI business analytics team in its delivery of best-in-class analytics in the biopharmaceutical, preference-based marketing space.

He joins MTI from First Equity Card Corp., where he served as head of analytics.

▶ TECHNOLOGY POOL

Joann FLYNN

Elna HAMP

QFORMA ADDS TWO TO MANAGEMENT TEAM

Qforma, a provider of advanced analytics and pre-



USE YOUR QR CODE READER
OR GO TO
bit.ly/PV0511-Pool



2nd

Social Media for Pharma

Transitioning From Preparation to Implementation with Social Media Strategy

June 7-8, 2011 | Philadelphia, PA

Attending this Conference will Enable You to:

- **Understand** recent enforcement brought on by the FDA guidance surrounding digital media usage
- **Discuss** trends in social media and how they can advance the pharmaceutical industry
- **Evaluate** how implementing a social media strategy into your marketing plan will impact your organization's brand awareness
- **Improve** communication with patients and physicians by exploring different social media outlets

Featured Speakers Include:

- **Glenn N. Byrd**, Senior Director Regulatory Affairs, **MedImmune LLC**
- **Xavier Petit**, Integrated Marketing - Multi-Channel Strategy Services, **Shire US**
- **Kristina Broadbelt**, Global Director, Public Relations & Advocacy, **ViroPharma**
- **Amit Pherwani**, Manager, Direct Marketing, **Bristol-Myers Squibb**

This is not a trade show; our Social Media for Pharma series is targeted at a focused group of senior level executives to maintain an intimate atmosphere for the delegates and speakers. Since we are not a vendor driven conference, the higher level focus allows the delegates to network with their industry peers and speakers.

“Establish
a strong DTC marketing approach
and brand recognition by utilizing a
robust social media strategy.”

Implementing a strong social media platform within your organization while maintaining FDA compliance.

marcusevans

Follow Us:



marcusevans conferences

For More Information, Please Contact:
Michele Westergaard
E: Michelew@marcusevans.com
T: 312 540 3000 ext. 6625

▶ BIOTECHNOLOGY POOL

Chip CLARK

GENOCEA PROMOTES CHIEF EXECUTIVE

Genocea Biosciences, a vaccine discovery and development company pioneering a new class of T-cell-based vaccines, has promoted Chief Business Officer Chip Clark to president and CEO. Before joining Genocea in August 2010, Mr. Clark was chief business officer at Vanda Pharmaceuticals, a biopharmaceutical company he co-founded in 2004. He received an MBA from The Wharton School of the University of Pennsylvania.

Dr. Marvin HAUSMAN

GENESIS BIOPHARMA APPOINTS SCIENCE CHIEF

Genesis Biopharma, a biotechnology company focused on developing targeted cancer therapies, has appointed Marvin Hausman, M.D., chief science officer. Dr. Hausman has 30 years of drug development and clinical care experience at various pharmaceutical companies, most recently serving as chairman and CEO of Total Nutraceutical Solutions. He received an M.D. from New York University School of Medicine.

Gary OTTO

CYTOMEDIX EXPANDS ACCOUNTS TEAM

Cytomedix, a developer of biologically active regenerative therapies for wound care and tissue repair, has appointed Gary Otto director of national accounts. Mr. Otto is responsible for all aspects of the company's commercial business with customers such as healthcare networks, group purchasing organizations, U.S. government accounts, and managed care organizations. He joins Cytomedix after 10 years with the national accounts team at CSL Behring.

▶ BIOPHARMACEUTICAL POOL

Dr. James BURKE

JENNEREX SELECTS R&D HEAD

Jennerex, a clinical-stage cancer biotherapeutics company, has named James Burke, M.D., VP, clinical research. Dr. Burke was previously director of cancer research at Billings Clinic. He received an M.D. from Georgetown University and has authored more than 10 key publications and presentations detailing the use of gene therapy and oncolytic viruses to treat cancer.

Dr. Sherwood GORBACH

Dr. Marc LESNICK

Dr. Glenn TILLOTSON

OPTIMER ANNOUNCES EXECUTIVE ADDITIONS, PROMOTIONS

Optimer Pharmaceuticals, a biopharmaceutical company focused on discovering, developing, and commercializing hospital specialty products to treat serious infections, has promoted Sherwood Gorbach, M.D., to chief scientific officer and senior VP of research and development. Dr. Gorbach joined Optimer in 2005 as chief medical officer.

A renowned authority on infectious diseases, Dr. Gorbach has published 600 papers and 19 books and is editor-in-chief of the journal *Clinical Infectious Diseases*. He received an M.D. from the Tufts University School of Medicine.

In other moves, Marc Lesnick, Ph.D., has been promoted to VP of regulatory affairs, from director of regulatory affairs. Dr. Lesnick has been with Optimer since 2008. He received a Ph.D. in biology from the University of Oregon.

Former ViroPharm executive Glenn Tillotson, Ph.D., has joined Optimer as senior VP of medical affairs, responsible for leading the medical affairs team and providing medical education and leadership to support optimal positioning of fidaxomicin for the treatment of *Clostridium difficile* infection. He received an M.S. in medicine from the University of Manchester's School of Medicine and a Ph.D. from Richmond University in London.

Jason KOLBERT

NEOSTEM ADDS BUSINESS DEVELOPMENT VP

International biopharmaceutical company NeoStem has appointed Jason Kolbert VP of strategic business development. Mr. Kolbert joins NeoStem from National Securities, where as a managing director he founded the firm's research effort in emerging biotechnology companies. He earned an MBA in finance from the University of New Haven.

With operations in the United States and China, NeoStem is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development, and transportation of adult stem cells for cell-based medicine and regenerative science worldwide.

▶ SPECIALTY POOL

Ronald RITZ

HEMISPHERX APPOINTS MANUFACTURING DIRECTOR

Hemisphere Biopharma, a specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities to treat seriously debilitating disorders, has named Ronald Ritz senior director of manufacturing. Mr. Ritz previously served as senior director of techni-

cal operations at Enzon Pharmaceuticals. He holds an MBA from Fairleigh Dickenson University.

▶ DIAGNOSTIC POOL

Doug BRADLEY

David MACDONALD

Mark WILLIG

AGENDIA EXPANDS OPERATIONS, MARKETING LEADERSHIP

Global molecular cancer diagnostics company Agendia has announced the addition of three executives to its operations and marketing leadership.

As VP of global marketing for Agendia, Doug Bradley manages all strategic and tactical marketing activities. Mr. Bradley was most recently VP of marketing at Vertos Medical. He received an MBA from Pepperdine University.

David Macdonald, who previously served as a consultant to Agendia, has formally joined the company as chief operating officer. Mr. Macdonald continues to be responsible for Agendia's laboratory operations, research and development, product support, information technology, and U.S. human resources. He received an MBA in marketing and entrepreneurship from Babson College.

Mark Willig has been named executive VP of North American sales. Mr. Willig has held a number of sales leadership positions within the healthcare industry, including VP of global sales for Thermo Fisher's anatomic pathology business unit and VP of sales at Myriad Genetics, as well as 12 years in commercial roles of increasing responsibility for Abbott Diagnostics.

▶ AGENCY POOL

Virginia COX

Dr. Todd MCINTYRE

3D COMMUNICATIONS STRENGTHENS REGULATORY EXPERTISE

3D Communications has added two executives to its team of regulatory and communications experts.

Virginia Cox has more than 15 years of experience in both the private and public healthcare sectors, and has worked at senior levels at the U.S. Food and Drug Administration (FDA), the U.S. Department of Health and Human Services (HHS), and at the Consumer Healthcare Products Association (CHPA), the trade group representing over-the-counter medicine (OTC) manufacturers. She received a law degree from Georgetown University.

Before joining 3D, Todd McIntyre, Ph.D., was most recently a senior regulatory consultant specializing in preparing pharmaceutical companies

for FDA advisory committee meetings and submissions to the FDA, the European Union's Committee for Medicinal Products for Human Use, and Japan's Ministry of Health, Labor and Welfare. Dr. McIntyre received a Ph.D. from the University of Colorado Boulder and served as a staff fellow at the National Institutes of Health.

▶ CONSULTING POOL

Caroline VOLPE

HEALOGIX APPOINTS MANAGING DIRECTOR

Healogix, a full-service custom marketing research consultancy for the pharmaceutical and biotechnology industries, has appointed Caroline Volpe managing director. Ms. Volpe is responsible for working with Healogix's growing portfolio of clients to help them achieve a competitive position through customized market research methodologies.

Ms. Volpe most recently served as a senior director at Genactis. She received an M.S. in marketing from Drexel University.

▶ SERVICE POOL

Linda ANDERSON
Dr. Marsha JONES
Dr. Teresa WAGNER

DRUG SAFETY ALLIANCE ADDS TO EXECUTIVE, RISK MANAGEMENT TEAMS


Drug Safety Alliance (DSA), a global provider of safety and risk management services supporting pharmaceutical, biotech, medical device, consumer health, and animal health organizations, has made several additions to its staff.

Linda Anderson has joined DSA as VP, quality and regulatory compliance. Ms. Anderson's responsibilities include providing overall leadership for the company's quality and regulatory compliance programs and maintaining its quality management system.

Ms. Anderson has more than 25 years of experience in regulatory compliance and drug development, most recently as senior director of regulatory compliance for Gilead Sciences. She received an MBA from the University of Richmond.

Marsha Jones, M.D., has been named medical director in DSA's safety and risk management team. Dr. Jones provides medical review of clinical and postmarketing safety reports and analyzing aggregate data, possible trends, new adverse events and/or changes in severity, frequency, or outcome of known adverse events associated with DSA's client products.

Dr. Jones has more than 20 years of clinical and pharmaceutical research experience, providing medical support and guidance across multiple clinical departments for companies including Telik, PPD, and GlaxoWellcome Pharmaceuticals (now GlaxoSmithKline). She received an M.S. in medical technology and hematology and an M.D. from the Medical College of Virginia/Virginia Commonwealth University.

Teresa Wagner, Ph.D., has been appointed director of global case processing, responsible for directing and supervising the operations, resources, timelines, and personnel involved in pharmacovigilance, clinical, and postmarketing case processing. Dr. Wagner was most recently employed by the Copernicus Group Independent Review Board. She holds an MBA and a Ph.D. in business management from Ashwood University. 

GLOBALclinicalTRIALS 

2nd Annual Executing Global Clinical Trials

September 15 - 16, 2011

Loews Philadelphia Hotel, Philadelphia, PA

How to Globalize Your Study for Clinical Success

Addressing

- ✓ Where the clinical, commercial and therapeutic opportunities are outside the US
- ✓ The whole scope of a global trial - regulations, country specific feasibility, infrastructure, partnerships, training, support, diversity of locations, patients, and culture
- ✓ Ensuring human subject protection is safe

Country-Specific Round Tables

China • India • Middle East • South America (Brazil) • Eastern Europe • Turkey • Russia/Ukraine

2011 Advisory Board

Amgen • BMS • Forest Research Laboratories • Genzyme • Otsuka America • Pfizer • Purdue • Roche
Takeda Global Research & Development • Talecris Biotherapeutics • Vical Therapeutics • Vital Therapies, Inc

Media Partner:

Pharma **VOICE**

Organized by:

THE **conference** FORUM 

TO REGISTER OR FOR MORE INFORMATION ON EITHER EVENT, VISIT
WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580

PharmaVoice
readers get 15% off
with code PVGCT